Total Utang marang Modal Coeptis Therapeutics (COEP)

Coeptis Therapeutics - logo grafis emiten COEP

Coeptis Therapeutics (COEP) is actively developing personalized methods for combating hematological tumors in the R&D stage. The company's price chart demonstrates the 0.02 indicator. The business relies on external contractors for drug production and the conduct of trials. Simultaneously, the brand is strengthening its image as an innovator by creating platforms to enhance patient immunity in the fight against blood cancer.

Coeptis Therapeutics Inc. (COEP): Rasio Utang marang Ekuitas saka 28.04.2023 nganti 09.05.2026

Rincian metrik lan analitis perusahaan Coeptis Therapeutics, Inc. (COEP)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Coeptis Therapeutics Inc.|COEP - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Coeptis Therapeutics|COEP - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Coeptis Therapeutics|COEP - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku coeptistx.com|COEP - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Coeptis Therapeutics|COEP - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Coeptis Therapeutics Inc.|COEP - Kewajiban utang agregat|Utang marang nilai buku Coeptis Therapeutics|COEP - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Coeptis Therapeutics|Likuiditas cepet coeptistx.com
- data bathi resik lan rasio valuasi:
COEP - Bathi resik perusahaan
Pambiji fundamental perusahaan:Coeptis Therapeutics
Produk dadi Coeptis Therapeutics Inc.

This indicator is calculated as the ratio of total liabilities to net equity, reflecting the dependence of operational stability on external financing. For Coeptis Therapeutics (COEP), which develops advanced blood cancer therapies, this debt-to-equity coverage ratio demonstrates the balance between investments in R&D-intensive developments and insolvency risks amid market volatility.

Analisis pesaing Coeptis Therapeutics

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Syndax Corp (SNDX)|Utang marang Ekuitas Kura Oncology, Inc. KURA|ADCT: Rasio Utang marang Ekuitas|Foghorn - Total Utang marang Modal|Vor Biopharma, Inc. (VOR) - Rasio Total Utang marang Ekuitas|NKTX: Total Utang marang Modal|Utang marang Modal Actinium Corp (ATNM)|Utang marang Ekuitas Estrella Immunopharma|CASI: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)